NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of...
NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of...
NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of...
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared...
NEJM at ESMO — Ponsegromab in Cancer Cachexia
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
